Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 04, 2021 08:00 ET | Source: Pharvaris N.V.

Pharvaris to Participate in BioCapital Europe

ZUG, Switzerland, March 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for...
February 26, 2021 08:00 ET | Source: Pharvaris N.V.

Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE

ZUG, Switzerland, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for...
February 19, 2021 10:00 ET | Source: Pharvaris N.V.

Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE, at the AAAAI Annual Meeting

ZUG, Switzerland, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative...
February 09, 2021 16:05 ET | Source: Pharvaris N.V.

Pharvaris Announces Closing of Initial Public Offering

ZUG, Switzerland, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris”) (Nasdaq: PHVS), a clinical-stage biopharmaceutical company focused on the discovery, development, and...
February 04, 2021 20:08 ET | Source: Pharvaris N.V.

Pharvaris Announces Pricing of Upsized Initial Public Offering

ZUG, Switzerland, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative...